01877 JUNSHI BIO
- 13.540
- -0.240-1.74%
JUNSHI BIO News
Institutions Profited After Shanghai Junshi Biosciences Co., Ltd.'s (HKG:1877) Market Cap Rose HK$1.6b Last Week but Individual Investors Profited the Most
Key Insights Significant control over Shanghai Junshi Biosciences by individual investors implies that the general public has more power to influence management and governance-related decisions The
Junshi Biotech (688180.SH): A total of 781,500 shares have been repurchased
Gelonghui, April 30, 丨 Junshi Biotech (688180.SH) announced that as of April 30, 2024, the company had repurchased 781,486 shares through centralized bidding transactions, accounting for 0.0793% of the company's total share capital. The highest repurchase transaction price was RMB 41.69 per share, the lowest price was RMB 29.21 yuan/share, and the total amount of capital paid was RMB 29,883,225.58 (excluding transaction fees such as stamp duty and transaction fees).
Changes in Hong Kong stocks | Junshi Biotech (01877) rose more than 6% in the afternoon, Q1 revenue increased 49.24% year-on-year, and losses narrowed by 47.92%
The Zhitong Finance App learned that Junshi Biotech (01877) rose more than 6% in the afternoon. As of press release, it had risen 4.24% to HK$11.3, with a turnover of HK$14.146,600. According to the news, Junshi Biotech announced its results for the first quarter of 2024, with operating income of about 381 million yuan, an increase of 49.24%; net loss attributable to shareholders of listed companies was about 283 million yuan, a year-on-year narrowing of 47.92%; and a basic loss of 0.29 yuan per share. During the reporting period, the increase in the company's revenue was mainly due to the increase in sales revenue of commercial drugs. Among them, the core product, treprilizumab injection (
君實生物：海外監管公告 - 上海君實生物醫藥科技股份有限公司2024年第一季度報告
Junshi Biotech (688180.SH): Net loss of 283 million yuan in the first quarter
Gelonghui, April 29丨Junshi Biotech (688180.SH) released its first quarter report. Operating revenue was 380 million yuan, up 49.24% year on year, net loss of 283 million yuan, net loss of 307 million yuan after deducting non-net loss of 307 million yuan, and basic earnings per share.
君實生物：2023年度報告
Shanghai Junshi Biosciences Receives Hong Kong Approval for Cancer Drug Toripalimab
Hong Kong's Department of Health has approved a new drug application for Shanghai Junshi Biosciences' (SHA:688180, HKG:1877) cancer drug toripalimab, according to a Wednesday release filed with the Ho
Changes in Hong Kong stocks | Innovative drug concept stocks rose higher, Keji Pharmaceutical-B (02171) rose more than 11%, and innovative drugs ushered in a full-process support mechanism
Innovative drug concept stocks continued to rise. As of press release, Keji Pharmaceutical-B (02171) rose 10.3% to HK$5.57; Laikai Pharmaceutical-B (02105) rose 9.15% to HK$6.44; and Rongchang Biotech (09995) rose 6.29% to HK$31.25.
Junshi Biosciences Announces NDA Acceptance in Hong Kong for Toripalimab
SHANGHAI, China, April 24, 2024 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences," HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the
Junshi Biotech (01877) appoints Wang Zhengyu as board secretary
Zhitong Finance App News, Junshi Biotech (01877) issued an announcement. Due to career development reasons, Chen Yingge applied to resign as secretary of the company's board of directors, joint company secretary and authorized representative. The resignation took effect from the date it was delivered to the company's board of directors. After Chen Yingge's resignation, he will no longer hold any position in the company. Furthermore, after the qualification review of the nomination committee of the 3rd board of directors of the company, the company held the 30th meeting of the 3rd board of directors on April 24, 2024 to review and pass the “Proposal on Appointing the Company's Board Secretary, Joint Company Secretary and Authorized Representative”. The details are as follows: Wang Zhengyu was appointed as the secretary of the company's board of directors
Junshi Biotech (01877.HK) plans to hold a board meeting on April 29 to approve the first quarter results
Gelonghui, April 17, 丨 Junshi Biotech (01877.HK) issued an announcement. The board of directors hereby announces that it will hold a board meeting on April 29, 2024 (Monday) to consider and approve the Group's unaudited financial results for the three months ended March 31, 2024.
君實生物：董事會召開日期
Junshi Biotech (688180.SH): Up to now, the company has no oral antihypertensive drug research and development projects
Gelonghui, April 10 | Junshi Biotech (688180.SH) said on the investor interactive platform that up to now, the company has no oral antihypertensive drug research projects.
There's No Escaping Shanghai Junshi Biosciences Co., Ltd.'s (HKG:1877) Muted Revenues
You may think that with a price-to-sales (or "P/S") ratio of 6.8x Shanghai Junshi Biosciences Co., Ltd. (HKG:1877) is a stock worth checking out, seeing as almost half of all the Biotechs companies in
Cansino Biotech (06185), the leading healthcare market, surged 15.12%, and Beijing, Guangzhou, and Zhuhai issued pharmaceutical innovation support policies
Jinwu Financial News | The healthcare sector led the market. Hang Seng Healthcare Index rose 1.93%. Among the constituent stocks, Cansino Biotech (06185) rose 15.12%, Junshi Biotech (01877) rose 11.9%, Genting Xinyao (01952) rose 7.8%, Yiming Angke (01541) rose 7.79%, Pharmaceuticals (02268) rose 5.98%, and Tiger Pharmaceuticals (03347) rose 5.8%. According to the news, the Beijing Municipal Medical Security Administration issued “On “Certain Measures to Support the High-Quality Development of Innovative Pharmaceuticals by 9 Departments Including the Beijing Municipal Medical Security Administration” (202
Changes in Hong Kong stocks | Junshi Biotech (01877) rose more than 6%, and approval of Trepri for kidney cancer is expected to boost sales
Junshi Biotech (01877) rose more than 6%. As of press release, it rose 6.65% to HK$10.58, with a turnover of HK$8.916 million.
Junshi Biosciences Gets Nod to Register Toripalimab Injection
Shanghai Junshi Biosciences (HKG:1877, SHA:688180) obtained a drug registration certificate for its toripalimab injection from China's National Medical Products Administration, according to the compan
Changes in Hong Kong stocks | Junshi Biotech (01877) rose nearly 5%, triplizumab combination therapy approved for first-line treatment of kidney cancer
Junshi Biotech (01877) rose nearly 5%. As of press release, it rose 4.73% to HK$10.18, with a turnover of HK$3.3764 million.
Junshi Biotech: Application for marketing of treprilizumab as a new indication for first-line treatment of renal cell carcinoma was approved
Junshi Biotech (01877) issued an announcement. The company received the “Drug Registration Certificate” approved and issued by the State Drug Administration, and the marketing application for treprilimab (trade name: Tuoyi, product code: JS001) combined with axitinib for first-line treatment of medium- to high-risk patients with unresectable or metastatic renal cell cancer was approved. It is the first approved immunotherapy for kidney cancer in China.
Junshi Biosciences Announces Approval of the SNDA for Toripalimab for the 1st-Line Treatment of Renal Cancer
SHANGHAI, China, April 07, 2024 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences", HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the National Medical Products Administration ("NMPA") has approved the supplemental new drug application ("sNDA") for toripalimab (product code: JS001) in combination with axitinib for the first-line treatment of patients with medium to high risk unresectable or metastatic renal cell carcinoma ("RCC").
Analysis
Price Target
No Data
